Evommune Q2 net loss $32.2M; EVO756 AD Phase 2b data due Sept 2026

Evommune, Inc.

Net loss of $32.2M for Q2 2026 vs $13.6M in Q2 2025; cash $288M as of June 30, 2026.
EVO756 Phase 2b top-line data in moderate-to-severe atopic dermatitis expected September 2026.
EVO756 migraine prophylaxis Phase 2b trial initiated; top-line data anticipated in 2027.
Discontinued EVO756 development in chronic spontaneous urticaria after Phase 2b missed primary endpoint.
EVO301 Phase 2a full positive data set in AD to be presented at upcoming medical conference; Phase 2b to start mid-2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.